Background This randomized phase II study compared the efficacy and toxicity between 4-week and 3-week schedules of gemcitabine monotherapy in advanced pancreatic cancer. Methods Patients with advanced pancreatic cancer were randomly assigned to either a 4-week schedule (gemcitabine at 1000 mg/m 2 as a 30-min infusion weekly for 3 consecutive weeks every 4 weeks) or a 3-week schedule (gemcitabine at 1000 mg/m 2 as a 30-min infusion weekly for 2 consecutive weeks every 3 weeks). The primary endpoint was the compliance rate during the first 8 weeks between the two groups. Results A total of 90 patients were enrolled. The compliance rate during the first 8 weeks was the same (53.3%). For the 4-and 3-week schedules, the tumor response rates were 14.2 and 17.1% (p = 0.92), median progression free survival was 112 and 114 days (p = 0.82), and median overall survival was 206 and 250 days (p = 0.84), respectively. Grade 3-4 neutropenia was the major adverse event in both schedules: 37.7 and 35.5% (p = 0.82). In contrast, thrombocytopenia (platelet count \70000/mm 3 ) was significantly higher for the 4-week schedule: 26.6 and 4.4% (p = 0.008). The mean received dose intensity was equal: 588 and 550 mg/m 2 /week (p = 0.14). Conclusions The 3-week schedule of gemcitabine did not improve the compliance rate during 8 weeks compared with the 4-week schedule, but it attained a comparable efficacy with lower toxicity. Further investigation will be needed to introduce it into daily practice. Clinical trial registration number: UMIN ID 974.
Introduction
Pancreatic cancer is the eighth most common cause of cancer-related death worldwide, and represents one of the most lethal cancers [1] , with a 5-year survival rate of less than 5-6% [2] [3] [4] . The only treatment capable of achieving a complete cure is successful and complete surgical resection, but since most cases of the disease are at an advanced stage when diagnosed, they cannot be successfully resected, and patients are thus subjected to chemotherapy. However, until the introduction of gemcitabine (difluorodeoxycytidine; dFdC), the efficacy of chemotherapy had not been encouraging [5] .
Gemcitabine, which is a nucleoside analog with activity in a broad spectrum of solid tumors, has been accepted as the standard treatment for advanced pancreatic cancer with survival benefit versus fluorouracil [6] . Since the initial approval of gemcitabine, there have been several randomized phase III trials of gemcitabine-based combinations in an attempt to improve survival outcomes over those achieved with gemcitabine alone; however, these combinations have shown no or only a modest survival advantage [7] [8] [9] [10] . Accordingly, gemcitabine monotherapy is still the treatment of choice for unresectable pancreatic cancer, especially for elderly patients or those with a diminished capacity to endure the toxic effects of combination therapy. Despite its potent anti-tumor efficacy, gemcitabine monotherapy seldom produces complete remission for patients with pancreatic cancer. Therefore, the agent must be administered to the patient for as long as it is effective. However, special attention should continue to be paid to these patients, because gemcitabine also has side effects. Dose modification and schedule changes are often required to avoid cessation of this treatment in order to achieve long-term treatment.
In Japan, one of the most commonly used schedules for gemcitabine monotherapy is the 4-week schedule, which delivers gemcitabine at 1000 mg/m 2 as a 30-min infusion weekly for 3 consecutive weeks every 4 weeks [11] . This schedule seems to represent a safe, tolerable and effective regimen. However, dose reductions and dosing interval adjustments based on adverse events are often necessary in clinical practice. To avoid adverse effects, we have sometimes used a 3-week schedule in our clinical practice (gemcitabine at 1000 mg/m 2 as a 30-min infusion weekly for 2 consecutive weeks every 3 weeks). To verify the efficacy and toxicity of this schedule, we conducted a randomized phase II study to compare the toxicity and dose intensity (DI) between the 4-week and 3-week schedules of gemcitabine monotherapy in patients with advanced pancreatic cancer.
Patients and methods

Eligibility criteria
This study was designed to enroll patients with unresectable, histologically or cytologically proven, locally advanced or metastatic pancreatic adenocarcinoma. Other eligibility criteria included no prior therapy, Karnofsky performance status C50%, age between 20 and 80 years, life expectancy of more than 2 months, and adequate organ function defined as white blood cell (WBC) count C3000/mm 3 , neutrophils C1500/mm 3 , platelets C100000/mm 3 , hemoglobin C9.0 g/dl, total bilirubin B2.0 mg/dl (or B3.0 mg/dl if biliary drainage was present), AST and ALT B2 times the upper limit of normal (or B5 times the upper limit of normal if liver metastasis was present), and creatinine B the upper limit of normal. This study was performed in accordance with the Declaration of Helsinki and approved by the local ethical committees of the participating institutions. Written informed consent was obtained from all patients.
Randomization
The patients who fulfilled all inclusion criteria were registered by the attending physician at the coordinating institution. Randomization was performed centrally, and the random-allocation sequence had been generated previously by a statistician using a computer-generated random code. The patients were stratified by their Karnofsky performance status (\80 vs. C80 points) and age (\70 vs. C70 years); the trial was unblinded.
Pretreatment and follow-up evaluation A pretreatment evaluation was performed which included the patient's medical history, a physical examination, electrocardiogram, complete blood cell counts (CBC) with differential WBC and platelet counts, blood chemistry including liver and renal functional parameters, and urine analysis. During chemotherapy, physical examination, CBC, and blood chemistry analyses were performed prior to administration of gemcitabine every time. Objective tumor assessments including spiral computed tomography (CT) of the abdomen and chest X-rays were performed at baseline and every 4 weeks thereafter.
Treatment schedules
Eligible patients were randomly assigned to either the 4-week or 3-week schedule of gemcitabine monotherapy. For the 4-week schedule, gemcitabine was administered intravenously at 1000 mg/m 2 as a 30-min infusion on days 1, 8 and 15 of a 28-day cycle, whereas in the 3-week schedule, gemcitabine was administered at the same dose on days 1 and 8 of a 21-day cycle. On both schedules, treatment courses were continued until the patients achieved an objective response or until those with stable disease developed progressive disease (based on the deterioration of their general condition or their CT images). Dexamethasone (8 mg) and granisetron (3 mg) were routinely administered as pre-treatments before gemcitabine administration.
Toxicity was graded according to the Common Terminology Criteria for Adverse Events version 3.0. To avoid adverse events, dose reductions and dosing interval adjustments were made on the basis of the worst toxicity observed during the previous cycle. When grade 3-4 hematological toxicity (defined as a platelet count \70000/mm 3 , rather than \50000/mm 3 , based on a report of a late phase II study in Japanese patients with lung cancer [12] ) or grade 2-4 non-hematological toxicity was noted, administration was postponed for a week. The gemcitabine dose was then reduced by 200 mg/m 2 from the previous dose, with a minimum dose of 400 mg/m 2 . A dose increase in these patients was not permitted even when no adverse effect was detected after dose reduction. A delay in the cycle of up to 2 weeks during one course was allowed when grade 2-4 hematological toxicity was recorded on day 1 of each cycle. When recovery from treatment-related toxicity required more than 2 weeks, the gemcitabine treatment was stopped. Supportive therapies, such as blood-product transfusion and the administration of antibiotics, antiemetics and analgesics, were performed whenever they were necessary. Hematopoietic growth factors were permitted in the presence of grade 4 neutropenia.
Evaluation of the response to treatment
According to the Response Evaluation Criteria in Solid Tumors [13] , the tumor response was assessed using spiral CT every 4 weeks by two radiologists blinded to the treatment assignment. A complete response was defined as the complete disappearance of all measurable and assessable lesions for at least 4 weeks. A partial response was defined as a C30% reduction in lesions, and stable disease was defined as a\30% reduction or a\20% increase in the sum of the longest diameter of all measurable lesions for at least 4 weeks. Progressive disease was defined as a C20% increase or the appearance of new lesions. The disease control rate was defined as the proportion of patients without progressive disease for 2 months. Primary pancreatic lesions were considered to be assessable but not measurable lesions. In such cases, only the disease control rate was assessed. Progression-free survival (PFS) was calculated from the day of randomization until death or evidence of clinical progression or tumor progression as assessed by CT scan. Overall survival (OS) was calculated from the day of randomization until death.
Calculation of dose intensity
The dose intensity was calculated using the method described by Hryniuk [14] , which was the number of milligrams of drug delivered per square meter per week during the whole treatment from day 1 of the first cycle to the last cycle day (day 28 for the 4-week and day 21 for the 3-week schedules). The planned dose intensity for the 4-week schedule was 750 mg/m 2 /week, and that for the 3-week schedule was 667 mg/m 2 /week. In fact, all of the received dose intensity was calculated during the treatment interval between the date of first administration and the date of last administration plus 13 days as drug holidays. Accordingly, the initial dose intensity during the first 8 weeks was not the same between the two groups because of the difference in treatment interval including drug holidays, even if the received total dose was the same for each schedule (6000 mg).
Statistical analysis
The primary objective of this study was to compare the efficacy and toxicity of the 3-week schedule with the 4-week schedule. Accordingly, we set the primary endpoint of this study to be the compliance rate of gemcitabine administration in each group during the first 8 weeks, because the planned total gemcitabine dose during this interval was 6000 mg/m 2 in both schedules. The compliance rate was defined as the proportion of the patients in each group who did not have any toxicity that caused a delay of administration, such as grade 3-4 hematological toxicity or grade 2-4 non-hematological toxicity. The secondary endpoints were the response rate, toxicity, dose intensity, progression-free survival and overall survival. The main analyses were conducted under the intention-totreat principle. A planned sample size of 45 patients for each group was chosen using Simon's randomized phase II selection design [15] , because it would be able to demonstrate a 15% improvement in the compliance rate during the first 8 weeks from 40% of patients in the 4-week schedule and 55% of patients in the 3-week schedule (based on our previous clinical experience), at the significance level of a error 5% in a one-sided test with a power of 90%.
For the assessment of categorical data, such as the toxicity, clinical characteristics and response rate, the two groups were compared using chi-squared tests with Yates' correction. The dose intensity was compared using Student's t test. All probability values were calculated under two-sided tests. The survival curves were estimated with the Kaplan-Meier method and compared with the log-rank test between the two groups. Differences were assumed to be significant when P values were \0.05. The cutoff date used for the analysis was 1 year after the inclusion of the last patient (October 15, 2009).
Statistical analyses were done with SAS version 8 software. No interim analysis was planned or done, and no early-stopping rule was planned for this trial.
Results
Enrollment and patient characteristics
From January 2006 to October 2008, 90 patients were enrolled in this study and 45 patients were assigned randomly to each schedule group. The database for analysis of this study included all data obtained up to October 2009. At that time, gemcitabine monotherapy was stopped due to either patient death, adverse effects, or disease progression. Eighty-three deaths due to primary disease were counted. The study flow chart is demonstrated in the CONSORT diagram (Fig. 1) . The main reason for termination of the protocol was disease progression (n = 73), while adverse events led to the termination of the protocol in 14 patients. Ten patients in each schedule were excluded from the analysis of tumor response rate because they had no measurable lesions. All patients were followed up with respect to the toxicity and efficacy of chemotherapy until the end of the study. The characteristics of both patient groups are shown in Table 1 . There were no significant differences, except for a trend for the patients in the 4-week schedule group to have a higher serum CA19-9 level (P = 0.18) and a smaller body surface area (P = 0.14) at baseline.
Evaluation of toxicity
Treatment-related adverse events are listed in Table 2 . Hematological toxicity was the most frequent adverse event, the main one being severe neutropenia (grade 3-4). However, there were no significant differences between the two groups (P = 0.82). On the other hand, a significant difference (P = 0.008) was detected with regard to thrombocytopenia (defined as a platelet count \70000/mm No significant differences were observed between the two groups with regard to non-hematological toxicities. The main non-hematological toxicity was cholangitis, defined as treatment-related elevations in serum biliary enzyme levels with fever. In addition, four cases of interstitial pneumonia were recorded in the patients on the 4-week schedule and four cases of pyelonephritis were noted in the patients on the 3-week schedule.
Compliance rate and dose intensity Overall, gemcitabine was administered 1028 times, 527 times to patients on the 4-week schedule and 501 times to patients on the 3-week schedule. Dose modifications and interval adjustments were necessary in 60% of all patients (54/90). The compliance rate during the first 8 weeks was the same for each protocol: 53.3% (24/45) ( Table 2 ). The compliance rate during the whole treatment course was 37.7% for the 3-week schedule, which was not significantly different (P = 0.67). In addition, the median duration of the cumulative rate of adverse events was 35 days in the patients on the 4-week schedule and 49 days in those on the 3-week schedule, but this difference was not significant (P = 0.20; Fig. 2 ). The initial dose intensity during the first 8 weeks was significantly greater for the patients on the 4-week schedule (P = 0.034; Table 2 ) than for those on the 3-week schedule. However, this significance disappeared when we compared the mean received dose intensity of the two groups for the entire treatment course (P = 0.14; Table 2 ).
Response and survival
Response analysis was performed for 35 patients, and the disease control rate and survival analysis for 45 patients on each schedule, respectively (CONSORT diagram). No complete remissions (CR) were observed in either schedule (Table 3 ). There were no significant differences in the response rate (14.2% in the patients on the 4-week schedule and 17.1% in the 3-week schedule) or the disease control rate (60.0 and 62.2%) between the two groups. Regarding the intent-to-treat principle, there were also no significant differences in median progression-free survival (112 and 114 days), 1-year survival rate (26.5 and 25.0%), or median overall survival (206 and 250 days) in the patients on the two schedules (Fig. 3) .
These results seemed to show a higher response rate and longer overall survival in the 3-week schedule, although there were no statistically significant differences between two groups. However, the baseline level of CA19-9 tended to be higher in the 4-week schedule (Table 1) . Therefore, to exclude the possibility that the number of patients with far advanced morbidity may have been greater in the 4-week schedule, we conducted an additional analysis regarding the value of CA19-9. Among 68 patients whose CA19-9 level was under the 75th percentile (CA19-9 level B6031 U/ml, n = 31 in the 4-week schedule and n = 37 in the 3-week schedule), we analyzed the progression-free survival and overall survival of both schedules. The median overall survival of the two groups in this adjustment analysis became closer (260 and 277 days), although median progression-free survival times were the same as the results of the intention-to-treat analysis (112 and 114 days).
Discussion
Gemcitabine is a key drug for the treatment of advanced pancreatic cancer because it can lead to prolonged survival and a good clinical response. Nevertheless, its efficacy is limited and a complete cure generally cannot be attained by using this drug alone. To make the most of this drug, it is necessary to avoid adverse events and continue the treatment as long as possible. Therefore, we conducted this study to compare the efficacy and toxicity between two different treatment schedules, that is, one with a higher planned dose intensity of gemcitabine (the 4-week schedule) versus another with a lower planned dose intensity (the 3-week schedule). We expected a higher compliance rate for the 3-week schedule. Unfortunately, no difference between the two protocol regimens (primary endpoint) was found in the compliance rate at 8 weeks, because we were obliged to reduce the dose and to adjust the administration time within 4 weeks from the start of chemotherapy in both treatment groups. However, we found that the rate of hematological toxicity (defined by a platelet count \70000/mm 3 ) was significantly lower for patients on the 3-week schedule. In addition, we noticed that the cumulative rate of adverse events tended to be higher for the 4-week schedule than the 3-week schedule, although the mean received dose intensity was nearly equal, and the efficacy was almost the same between the patients on the different schedules.
It is a basic paradigm of chemotherapy that dose intensity should be kept as high as the patients can endure. From the results of this study, we do not intend to change it. We currently have to use gemcitabine, despite its limited efficacy and associated morbidity, because no other effective second-line drugs are available for advanced pancreatic cancer. The prognosis of pancreatic carcinoma is grim, and it is difficult to attain a CR from systemic chemotherapy. Nevertheless, chemotherapy, and gemcitabine in particular, has been shown to provide some clinical benefit. It is thus necessary to continue the treatment and avoid the need to abandon chemotherapy due to its adverse effects. Previously, a similar randomized phase II study with gemcitabine and cisplatin was conducted in patients with lung cancer and other malignant diseases. This study showed that the 3-week schedule of combination gemcitabine and cisplatin had an equal dose intensity and superior compliance profile to the 4-week schedule [16] . This further supports the conclusions about the feasibility and safety of the 3-week schedule demonstrated in our study. Although the initial dose intensity was lower in the 3-week schedule, we believe that our results demonstrate that we Overall DI 588 ± 130 550 ± 116 0.14 can recommend the 3-week schedule for elderly patients or those with complicated morbidities to decrease the possibility of treatment withdrawal due to adverse effects. Despite the fact that our study used gemcitabine monotherapy, the received dose intensity was lower than that reported for combination therapies using gemcitabine (4-week schedule) and 5-fluorouracil (our study: 588 mg/ m 2 /week for the 4-week schedule and 550 mg/m 2 /week for the 3-week schedule, compared with combination therapy: 601 mg/week/m 2 by Hidalgo et al. [17, 18] and 593 mg/ week/m 2 by Shiah et al. [17, 18] ). We assume that the lower dose intensity in our study was due to our protocol, which used dose reduction if toxic effects occurred, and defined the minimum dose of gemcitabine as 400 mg/m 2 . However, the efficacy of chemotherapy in our study was comparable with other reports [6] [7] [8] [9] [10] . Therefore, the minimal effective dose of gemcitabine may depend on the type of patients and whether they experience adverse effects. That is to say, the effective dose intensity may be defined as the maximal dose which does not induce adverse effects.
In conclusion, it was suggested that the 3-week schedule has comparable efficacy with lower toxicity. These results may support the efficacy of the other 3-week gemcitabinebased combination regimens. However, due to the nature of phase II studies, our study population was small. Therefore, we should not mention the survival benefits with the results of this study. Moreover, the primary endpoint defined by the 8-week compliance rate also did not meet the statistical hypothesis. Accordingly, the 3-week schedule of gemcitabine monotherapy is not recommended at present. Further investigation will be needed to introduce it into daily practice.
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